These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38534728)

  • 41. Upregulation of Galectin-9 and PD-L1 Immune Checkpoints Molecules in Patients with Chronic Lymphocytic Leukemia.
    Taghiloo S; Allahmoradi E; Ebadi R; Tehrani M; Hosseini-Khah Z; Janbabaei G; Shekarriz R; Asgarian-Omran H
    Asian Pac J Cancer Prev; 2017 Aug; 18(8):2269-2274. PubMed ID: 28843266
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification and characterization of distinct IL-17F expression patterns and signaling pathways in chronic lymphocytic leukemia and normal B lymphocytes.
    Sherry B; Jain P; Chiu PY; Leung L; Allen SL; Kolitz JE; Rai KR; Barrientos J; Liang S; Hawtin R; Chiorazzi N
    Immunol Res; 2015 Dec; 63(1-3):216-27. PubMed ID: 26478573
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Expression of CTLA-4 and CD86 Antigens and Epstein-Barr Virus Reactivation in Chronic Lymphocytic Leukemia-Any Link with Known Prognostic Factors?
    Grywalska E; Mielnik M; Podgajna M; Hymos A; Ludian J; Rolińska A; Gosik K; Kwaśniewski W; Sosnowska-Pasiarska B; Smok-Kalwat J; Pasiarski M; Stelmach-Gołdyś A; Góźdź S; Roliński J
    Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158937
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Beta2-microglobulin is a better predictor of treatment-free survival in patients with chronic lymphocytic leukaemia if adjusted according to glomerular filtration rate.
    Delgado J; Pratt G; Phillips N; Briones J; Fegan C; Nomdedeu J; Pepper C; Aventin A; Ayats R; Brunet S; Martino R; Valcarcel D; Milligan D; Sierra J
    Br J Haematol; 2009 Jun; 145(6):801-5. PubMed ID: 19388937
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Expansion of CMV-specific CD8+CD45RA+CD27- T cells in B-cell chronic lymphocytic leukemia.
    Mackus WJ; Frakking FN; Grummels A; Gamadia LE; De Bree GJ; Hamann D; Van Lier RA; Van Oers MH
    Blood; 2003 Aug; 102(3):1057-63. PubMed ID: 12689926
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biomarkers for checkpoint inhibition in hematologic malignancies.
    Atanackovic D; Luetkens T
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):198-206. PubMed ID: 29775689
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CLL-Derived Extracellular Vesicles Impair T-Cell Activation and Foster T-Cell Exhaustion via Multiple Immunological Checkpoints.
    Böttcher M; Böttcher-Loschinski R; Kahlfuss S; Aigner M; Gießl A; Mackensen A; Schlötzer-Schrehardt U; Tüting T; Bruns H; Mougiakakos D
    Cells; 2022 Jul; 11(14):. PubMed ID: 35883619
    [No Abstract]   [Full Text] [Related]  

  • 48. Preliminary analysis of double-negative T, double-positive T, and natural killer T-like cells in B-cell chronic lymphocytic leukemia.
    Valvano L; Nozza F; D'Arena G; D'Auria F; De Luca L; Pietrantuono G; Mansueto G; Villani O; D'Agostino S; Lamorte D; Calice G; Statuto T
    Cancer Med; 2023 Jun; 12(12):13241-13255. PubMed ID: 37140360
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immune Checkpoint Pathway Expression in Lymphocyte Subpopulations in Patients with Common Variable Immunodeficiency and Chronic Lymphocytic Leukemia.
    Mertowska P; Mertowski S; Smolak K; Kita A; Kita G; Guz K; Pasiarski M; Grywalska E
    Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958359
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Higher frequency of the CTLA-4
    Chen Y; Tan J; Huang S; Huang X; Huang J; Chen J; Yu Z; Lu Y; Weng J; Du X; Li Y; Zha X; Chen S
    Asia Pac J Clin Oncol; 2020 Apr; 16(2):e12-e18. PubMed ID: 31612643
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Expansion of a CD8(+)PD-1(+) replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression.
    Nunes C; Wong R; Mason M; Fegan C; Man S; Pepper C
    Clin Cancer Res; 2012 Feb; 18(3):678-87. PubMed ID: 22190592
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Global histone deacetylase enzymatic activity is an independent prognostic marker associated with a shorter overall survival in chronic lymphocytic leukemia patients.
    Van Damme M; Crompot E; Meuleman N; Mineur P; Dessars B; El Housni H; Bron D; Lagneaux L; Stamatopoulos B
    Epigenetics; 2014 Oct; 9(10):1374-81. PubMed ID: 25437053
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immune checkpoints are predominantly co-expressed by clonally expanded CD4
    Bredel D; Tihic E; Mouraud S; Danlos FX; Susini S; Aglave M; Alfaro A; Mohamed-Djalim C; Rouanne M; Halse H; Bigorgne A; Tselikas L; Dalle S; Hartl DM; Baudin E; Guettier C; Vibert E; Rosmorduc O; Robert C; Ferlicot S; Parier B; Albiges L; de Montpreville VT; Besse B; Mercier O; Even C; Breuskin I; Classe M; Radulescu C; Lebret T; Pautier P; Gouy S; Scoazec JY; Zitvogel L; Marabelle A; Bonvalet M
    J Exp Clin Cancer Res; 2023 Dec; 42(1):333. PubMed ID: 38057799
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Preparation of heat shock protein 70 (Hsp70) and idiotypic determinant single-chain antibody (Id-ScFv) in a patient with B-cell chronic lymphatic leukemia (B-CLL) and antitumor effect of peptide complex Hsp70-Id].
    Ye Q; Wang ZH; Qin SK
    Ai Zheng; 2008 Feb; 27(2):133-8. PubMed ID: 18279608
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Patients with chronic lymphocytic leukaemia (CLL) differ in the pattern of CTLA-4 expression on CLL cells: the possible implications for immunotherapy with CTLA-4 blocking antibody.
    Ciszak L; Frydecka I; Wolowiec D; Szteblich A; Kosmaczewska A
    Tumour Biol; 2016 Mar; 37(3):4143-57. PubMed ID: 26490985
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CD8+ T-cells Co-expressing PD-1 and TIGIT Are Highly Frequent in Chronic Lymphocytic Leukemia.
    Hajiasghar-Sharbaf R; Asgarian-Omran H; Valadan R; Hossein-Nattaj H; Shekarriz R; Zaboli E; Janbabaei G; Tehrani M
    Iran J Allergy Asthma Immunol; 2021 Dec; 20(6):751-763. PubMed ID: 34920658
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of prognostic variables in chronic lymphocytic leukemia and association with disease stage.
    Attia HRM; Ibrahim MH; El-Aziz SHA; Abdelrahman AH; Sobeih ME; Hagag HAA; Yassa ME; Osman RA; Rawi R; El-Dayem OYA; Elsharkawi N; Abdelfattah R; Hassan NM
    Mol Clin Oncol; 2021 May; 14(5):100. PubMed ID: 33796290
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Chronic Lymphocytic Leukemia B-Cell Normal Cellular Counterpart: Clues From a Functional Perspective.
    Darwiche W; Gubler B; Marolleau JP; Ghamlouch H
    Front Immunol; 2018; 9():683. PubMed ID: 29670635
    [TBL] [Abstract][Full Text] [Related]  

  • 59. PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness.
    He R; Ding W; Viswanatha DS; Chen D; Shi M; Van Dyke D; Tian S; Dao LN; Parikh SA; Shanafelt TD; Call TG; Ansell SM; Leis JF; Mai M; Hanson CA; Rech KL
    Am J Surg Pathol; 2018 Jul; 42(7):843-854. PubMed ID: 29762141
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Reduced prognostic value of beta-2-microglobulin for time to first treatment in CLL patients with compromised kidney function.
    Bohn JP; Stolzlechner V; Göbel G; Pirklbauer M; Wolf D; Steiner N
    Leuk Lymphoma; 2024 Dec; 65(14):2108-2115. PubMed ID: 39165182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.